Breast Cancer, Non-metastatic
Questions discussed in this category
Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits.
1793010144
Papers discussed in this category
N. Engl. J. Med.,
PloS one, 2017
Circulation, 2016-03-29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991 Feb
Journal of stroke, 2020 Jan 31